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Abstract
Differentiated mammary epithelium shows apicobasal polarity, and loss of tissue organization is an early hallmark of breast
carcinogenesis. In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased
risk of developing tumors of basal-like type suggest that BRCA1 regulates stem/progenitor cell proliferation and
differentiation. However, the function of BRCA1 in this process and its link to carcinogenesis remain unknown. Here we
depict a molecular mechanism involving BRCA1 and RHAMM that regulates apicobasal polarity and, when perturbed, may
increase risk of breast cancer. Starting from complementary genetic analyses across families and populations, we identified
common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies breast
cancer risk among BRCA1, but probably not BRCA2, mutation carriers: n=7,584, weighted hazard ratio (wHR)=1.09 (95% CI
1.02–1.16), ptrend=0.017; and n=3,965, wHR=1.04 (95% CI 0.94–1.16), ptrend=0.43; respectively. Subsequently, studies of
MCF10A apicobasal polarization revealed a central role for BRCA1 and RHAMM, together with AURKA and TPX2, in essential
reorganization of microtubules. Mechanistically, reorganization is facilitated by BRCA1 and impaired by AURKA, which is
regulated by negative feedback involving RHAMM and TPX2. Taken together, our data provide fundamental insight into
apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor
type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of
HMMR/RHAMM.
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Introduction
The mammary gland is composed of two epithelial cell lineages
that form an inner apicobasal-polarized luminal layer surrounded
by an outer, or basal, layer of contractile myoepithelial cells [1].
Epithelial cell subsets are likely maintained through a differenti-
ation hierarchy supported by an estrogen receptor (ER)-negative
mammary stem cell population enriched at the basal compartment
[2–7]. Cytoskeletal structures, including actin and intermediate
filament content, identify differentiated cells [8] and may therefore
contribute to differentiation. For example, the organization of
microtubules at adherens junctions is essential for the maintenance
of cell-to-cell contacts in apicobasal-polarized epithelial [9]. This
involves centrosome-dependent microtubule assembly followed by
release and capture at non-centrosome sites [10]. Therefore,
dynamic cytoskeletal reorganization may be critical to the terminal
differentiation of breast luminal epithelium. However, the
molecular determinants of this process and the link with
carcinogenesis remain unknown.
The common pathological features of breast tumors arising in
breast cancer 1, early onset (BRCA1) gene mutation carriers,
including the basal-like phenotype and ER negativity [11,12],
led to the proposition that BRCA1 function regulates stem/
progenitor cell proliferation and differentiation [13]. Recent
evidence supports this hypothesis. Cell proliferation and
differentiation are altered with BRCA1 depletion in the non-
tumorigenic MCF10A breast cell line [14] and with ex vivo
culture of primary mammary epithelial cells from BRCA1
mutation carriers [15]. Xenografts of primary mammary
epithelial cells depleted of BRCA1 show expansion of stem cells
with impaired luminal differentiation [16]. Expanded luminal
progenitor populations have also been detected in breast tissue
from BRCA1 mutation carriers [17] and, subsequently, proposed
as the target of transformation leading to basal-like tumors [18].
A more recent study has shown expanded basal progenitor cells
but also defects in luminal progenitor differentiation in these
carriers [19]. While it has been postulated that stem/progenitor
cells may have stringent requirements for high-fidelity DNA
damage repair [17], the potential contribution of BRCA1 to
other molecular events fundamental in differentiation remains to
be elucidated.
BRCA1-dependent ubiquitination, functioning as a heterodi-
mer with BRCA1-associated RING domain 1 (BARD1), down-
regulates assembly of centrosome microtubules in a mammary-
specific manner [20,21]. Xenopus brca1-bard1 attenuates the
function of a microtubule-associated protein called Xenopus
receptor for hyaluronan-mediated motility (xrhamm) [22].
Xrhamm is the ortholog of a candidate low-penetrance breast
cancer susceptibility gene product (RHAMM, HMMR gene) [23]
whose over-expression in tumors is associated with poor
prognosis and early age at diagnosis [23–25]. While xrhamm
regulates microtubule organization during meiosis [26],
RHAMM controls c-tubulin (TUBG1) recruitment [27] and
interphase microtubule dynamics [28]. Together, these observa-
tions suggest that BRCA1 might be involved in epithelial
differentiation by down-regulating centrosome microtubule
assembly, through RHAMM and TUBG1, and promoting the
cytoskeletal reorganization necessary for apicobasal polarization.
Conversely, loss of BRCA1 function might impair structural cues
of terminal differentiation and, consequently, increase risk of
breast cancer characterized by the basal-like tumor type. Here,
we conduct complementary analyses to demonstrate genetic,
molecular, and functional interactions between BRCA1/BRCA1,
HMMR/RHAMM, and additional centrosome components that
orchestrate cytoskeletal reorganization critical for epithelial
apicobasal polarization. These new insights may enhance our
understanding of mammary epithelial differentiation and the link
with breast carcinogenesis.
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Common Genetic Variation in HMMR Modifies Breast
Cancer Risk among BRCA1 Mutation Carriers
Although BRCA1 and BRCA2 function coordinately during
DNA damage response, genomic, transcriptomic, molecular, and
pathological features of breast tumors arising in BRCA1 and
BRCA2 mutation carriers suggest that carcinogenesis may occur
through perturbation of shared and distinct biological processes
[13,29]. Previous analysis of candidate genomic regions using a
linkage approach suggested specific modification of breast cancer
risk among BRCA1 mutation carriers by common genetic variation
at chromosome 5q33-34 [30]. Extension of this study supports the
original conclusion: a haplotype analysis in 27 families with
BRCA1 mutations revealed a nonparametric linkage score peak of
4.24 at the 5q34 region containing HMMR (Table S1); in contrast,
no evidence of linkage was observed among 16 families with
BRCA2 mutations (only a suggestive signal at 20 centiMorgans
distal of HMMR was detected, D5S408 nonparametric linkage
score=1.91).
Common breast cancer-predisposition alleles may differentially
modify breast cancer risk among BRCA1 and BRCA2 mutation
carriers [31–33]. To complement the linkage approach, we
evaluated the effect of common HMMR genetic variation [23]
on breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Following a pilot study in Italy and Spain, analysis of carriers
(n=11,609) collected through 24 study groups participating in the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
detected significant modification of breast cancer risk by HMMR
rs299290 variant among BRCA1, but not BRCA2, mutation
carriers: BRCA1 mutation carriers n=7,584, Cox proportional-
hazards regression model, hazard ratio (HR)=1.08 (95%
confidence interval (CI) 1.02–1.13), ptrend=0.004 (p2df=0.014), in
the same direction as originally detected in Ashkenazi Jewish
populations [23]; BRCA2 mutation carriers n=3,965, HR=1.03
(95% CI 0.96–1.10), ptrend=0.42 (p2df=0.67). For BRCA1 mutation
carriers, consistent effects were observed across centers with larger
sample sizes (Figure 1).
We performed a number of sensitivity analyses to investigate the
robustness of our results. First, since prophylactic oophorectomy
reduces the risk of breast cancer in BRCA1 mutation carriers by up
to 50% [34], we included this observation as a time-dependent
covariate in the analysis, and a significant association similar to the
one shown above was revealed: HR=1.09 (95% CI 1.03–1.16),
ptrend=4.5610
24. Second, a non-significant association, but in the
same direction, was identified when prevalent cases (defined as
those diagnosed with breast cancer more than five years before
recruitment) were excluded from the analysis: HR=1.06 (95% CI
0.99–1.15), ptrend=0.10. Finally, to investigate whether the
retrospective study design and the non-random sampling of
affected and unaffected mutation carriers introduce bias into the
HR estimates, the data were also analyzed using a weighted cohort
approach [35], which yielded similar results to those shown above:
BRCA1 mutation carriers wHR=1.09 (95% CI 1.02–1.16),
ptrend=0.017 (p2df=0.041) (wHR per study centre are detailed in
Table S2); BRCA2 mutation carriers wHR=1.04 (95% CI 0.94–
1.16), ptrend=0.43 (p2df=0.68). Examination of heterogeneity in
risk estimates across groups did not show significant differences
under the multiplicative model (phet$0.3). The association was
then evaluated according to the predicted functional consequences
of BRCA1 mutation type [36–40]. This analysis suggested an effect
in carriers of loss-of-function mutations expected to result in a
reduced transcript or protein level due to nonsense-mediated RNA
decay (n=4,636, wHR=1.08 (95% CI 0.99–1.19)), whereas
carriers of mutations likely to generate stable proteins with
potential residual or dominant negative function might not be
influenced (n=1,380, wHR=1.00 (95% CI 0.85–1.18)). While
studies have identified low-penetrance alleles that associate with
breast cancer risk in carriers of BRCA1 mutations and carriers of
BRCA2 mutations [32,33], specificities have also been detected
[31,33,40]. Here, the results of linkage and association studies
support a potential, specific genetic interaction between BRCA1
and HMMR (high- and low-penetrance mutations, respectively),
which could highlight a BRCA1-RHAMM function altered in
familial and sporadic breast carcinogenesis.
Analysis of public gene expression datasets suggests that the
rs299290 risk allele is associated with HMMR germline over-
expression (see also Table S3) [23]. However, while the rs299290
variant represents a missense change predicted to be benign
(V368A; concordant predictions for PolyPhen-2 [41] and SIFT
[42] were obtained), it is in linkage disequilibrium (according to
Figure 1. Effect of HMMR rs299290 variation on breast cancer
risk among BRCA1 and BRCA2 mutation carriers. Forrest plots
show HRs and 95% CIs of the additive model (rs299290 C allele) for all
participating centers ordered by sample size (n.30) of BRCA1 mutation
carriers (left panel, wHR per study center are shown in Table S2; right
panel, effect on BRCA2 mutation carriers). The size of the rectangles is
proportional to the corresponding study precision.
doi:10.1371/journal.pbio.1001199.g001
Author Summary
Mutations in two genes that were initially identified as
predisposing carriers to early-onset breast cancer, BRCA1
and BRCA2, cause similar perturbations in cellular respons-
es to DNA damage but predispose carriers to distinct
tumor types. Thus, the two genes may trigger different
carcinogenic processes. We have used genetic analyses of
affected families to uncover additional genetic variation
that is linked to the risk of developing cancer for carriers of
BRCA1 mutations. This variation falls within a centrosomal
gene, named HMMR. The protein product of HMMR, which
is called RHAMM, works in concert with BRCA1 to regulate
the structure of normal breast cells as they grow and
become polarized. This polarization process depends upon
a balance between the activities of BRCA1 and the Aurora
kinase A, with the kinase opposing BRCA1 function and
promoting growth. Our findings provide new insights into
the mechanism through which BRCA1 may promote
commitment of initially bipotent mammary cells towards
the luminal lineage, and how loss of this function may
predispose cells to become breast tumors of a basal-like
type.
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2=0.48) with rs299284
(R92C in Entrez accession number NP_036616), which is
predicted to be damaging. The minor allele frequencies of
rs299290 and rs299284 in HapMap Caucasian individuals are
29% and 16%, respectively. Since rs299284 is at the fourth base
position of HMMR exon 5, we evaluated the potential alteration of
the splicing pattern of this exon or the ratio of the alternative exon
4. Notably, exon 4 spans the microtubule-binding domain and has
been shown to be skipped with progression of myeloma and breast
cancer [43,44]. However, no differences were observed when
analyzing the splicing pattern of both exons in lymphocytes from
10 BRCA1 mutation carriers (Figure S1) and in public transcrip-
tome sequence datasets (unpublished data). Therefore, further
work may be warranted to conclusively define the causal
mutation(s) and its potential alteration of RHAMM levels or
function.
Association by ER Timor Status and Cytoskeletal
Reorganization during Epithelial Apicobasal Polarization
Breast tumors arising in BRCA1 mutation carriers are typically
ER-negative, whereas most tumors in BRCA2 mutation carriers
and sporadic cases are ER-positive [11,12]. Given the evidence
above, we next evaluated whether HMMR variation was
associated with ER tumor status in BRCA1 and/or BRCA2
mutation carriers. In data provided by several CIMBA groups
(Text S1), no ER-positive tumors were observed among rare
rs299290 homozygotes in BRCA1 mutation carriers (pinteraction
=0.006), whereas this bias was not observed in BRCA2 mutation
carriers (pinteraction=0.95) (Table S4). That is, despite the expected
differences in the frequency of tumor types between the two sets of
carriers, heterogeneity was observed in the distribution of
rs299290 genotypes in BRCA1, but not BRCA2, mutation carriers.
This result further suggests an interaction between BRCA1 and
HMMR that influences or regulates differentiation of breast
luminal epithelium. On the basis of these observations and the
published data presented above, we next investigated the
relationship between BRCA1/BRCA1 and HMMR/RHAMM
regulating apicobasal polarization (hereafter polarity/polariza-
tion).
The growth of nonmalignant human mammary epithelial cells,
such as MCF10A and HMT3522 S1, within three-dimensional
cultures containing reconstituted basement membrane (rBM)
recapitulates aspects of the terminal differentiation of mammary
luminal epithelia, including apicobasal polarization, growth arrest,
and milk production [45,46]. The cyst-like polarized structures
(hereafter termed acini) formed by these cell types may, however,
vary in the nature or degree of polarization and tight junction
formation and, unlike heterotypic cultures of stromal and epithelial
cells [47], do not form bilayered cellular organizations [48].
Importantly, disruption of BRCA1 function through shRNA-
mediated depletion impairs differentiation and promotes prolifer-
ation of MCF10A cells within rBM [14]. This seminal observation
has been supported by evidence from other models for
differentiation [15,16] and the examination of human mammary
epithelial cell populations [17]. However, to date, the molecular
contributions of BRCA1 to apicobasal polarization are largely
unknown. Thus, we utilized the growth of MCF10A cells in rBM
as a model for polarization, as determined by the apical
localization of centrosomes, basal deposition of CD49f (also
known as a6-integrin) and reduced expression of vimentin (VIM),
an intermediate filament associated with the basal lineage [49].
These attributes were also captured through quantitation of acini
size and circularity or shape factor (Figure S2).
As BRCA1 and RHAMM functions may intersect at the
organization of microtubules and centrosomes, these structures
were first examined in MCF10A cells grown on two-dimensional
(i.e., plastic) versus three-dimensional (i.e., rBM) cultures. In
plastic, microtubules were assembled at centrally located centro-
somes (Figure 2A). During polarization in rBM, however,
microtubule organization transitioned from centrosome-depen-
dent assembly in early stages of culture to concentrate at non-
centrosome sites, such as regions of cell-to-cell contact, in late
stages (Figure 2B). Centrosomes were repositioned from the
outside of cell clusters to apical surfaces and the eventual site of the
lumen (Figure 2B). This organization was maintained in polarized
acini (Figure 2B) and is comparable to the apical position of
centrosomes in mammary epithelial cells in vivo (see also Figure
S3A) [50]. Thus, polarization of MCF10A is associated with a
transition in the organization of microtubules from centrosome to
non-centrosome sites, consistent with observations in other
epithelial cells or tissues [9,10].
Complementary to the study of microtubules, the dynamics of
VIM were also examined during polarization. In accordance with
a shift from basal to luminal cytoskeletal structures, VIM
abundance was reduced concurrent with the transition to non-
centrosome-dependent microtubule organization (Figure 2C) and
the deposition of CD49f (Figure S2). Therefore, polarization
requires dynamic cytoskeletal organization. However, the mech-
anistic contribution of BRCA1 to this process remains unknown.
Cytoskeletal Reorganization Is Influenced by BRCA1 and
Microtubule-Associated Factors within Polarized Epithelia
As BRCA1 down-regulates centrosome microtubules by target-
ing microtubule-associated factors for proteasome-dependent
degradation [20,21], we hypothesized that this activity may be
important for the transition to non-centrosome-dependent assem-
bly that is essential for polarity [9,10]. To evaluate this hypothesis,
we first examined the impact of BRCA1 depletion on polarization
and cytoskeletal structures. In agreement with a previous report
[14], transduction of lentiviral-based shRNAs against BRCA1
expression (shRNA-BRCA1) impaired polarization; observed acini
in this condition were, on average, significantly larger and less
circular than controls (Figure 3A). Results were similar following
transduction of individual (two different sequences) or pooled
shRNAs, with transient or stable shRNA expression assays, and
over a time course of one or two weeks (Figures S4 and S5). In
addition, VIM and CD49f expression were increased and reduced,
respectively, in acini depleted of BRCA1 relative to controls
(Figure 3A and S6). Thus, loss of BRCA1 function may impair
polarization by altering intracellular cytoskeletal organization,
resulting in intermediate filament content consistent with the
characteristic basal-like tumor type.
While BRCA1 haploinsufficiency does not preclude the
formation of a functional luminal layer, the cytoskeletal structure
within luminal epithelia from BRCA1 mutation carriers might be
compromised. Accordingly, histologically normal breast tissue
from BRCA1 mutation carriers revealed elevation of ALDH1-
positive cells with reduced expression of cytoskeletal markers
(cytokeratins 18 and 14) and ER [16]. Given these observations,
we evaluated TUBG1 staining, as a centrosome marker, in breast
tissue paraffin sections from four affected BRCA1 mutation
carriers. Three hyperplastic lesions were identified that showed
abnormal localization of the centrosome when considering their
respective nuclei and lumen (Figure S3B). Although the number of
samples is limited, these results agree with the loss of polarity
observed in MCF10A cells after BRCA1 depletion.
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mechanistic contribution of BRCA1 to MCF10A polarization.
Should polarization require BRCA1-mediated reduction in
microtubule assembly at the centrosome, proteasome inhibition
may disrupt this transition, even in the presence of BRCA1. When
grown in rBM, the major phenotypic response of MCF10A cells to
proteasome inhibition (MG132, see Materials and Methods) was
growth ablation and/or retardation (unpublished data). However,
exposure to 100 nM of MG132 for short periods of time resulted
in abnormal acini that deviated from circularity with impaired
centrosome apical polarity (Figure 3B). Additionally, proteasome
inhibition altered centrosome structures, resulting in diffuse and
enlarged pericentrin (PCNT) organization (Figure 3B, arrows).
Thus, proteasome inhibition phenocopies aspects of BRCA1
depletion, which suggests that proteolytic degradation of BRCA1-
target(s), such as RHAMM [23], may be critical for polarization.
To further evaluate this, we examined the influence of BRCA1
depletion and proteasome inhibition on the abundance of
RHAMM and aurora kinase A (AURKA), a defined proteasome
target [51]. Importantly, both proteasome inhibition and BRCA1
Figure 2. Centrosome microtubule assembly is altered as MCF10A are cultured on two- or three-dimensional systems. (A)
Microtubule density (a-tubulin, TUBA) is concentrated around centrosomes (PCNT) within adherent MCF10A. (B) When grown in rBM, microtubule
density (TUBA and b-tubulin, TUBB) is initially (top panels, days 1–3 of culture) concentrated around centrosomes (deconvolved z-slices from
epifluorescence microscopy images, left panels; confocal microscopy images, right panels; E-cadherin, CDH1; and TUBG1). Upon apical localizationo f
centrosomes (middle panels, days 4–7), microtubule density is amplified at cell-to-cell contacts, as determined by CDH1. This organization is
maintained through acinar morphogenesis and lumen formation (bottom panels, after day 10). Scale bars represent 20 mm. (C) Reorganization of VIM
intermediate filaments during apicobasal polarization in rBM culture. Confocal images were acquired with equivalent settings to allow comparison of
intensities. Scale bars represent 20 mm.
doi:10.1371/journal.pbio.1001199.g002
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is also consistent with observed RHAMM over-expression in
breast cancer cell lines derived from BRCA1 mutation carriers
[23]. BRCA1 depletion, however, did not alter AURKA levels
(Figure S7). Thus, RHAMM abundance, which is responsive to
both BRCA1 depletion and proteasome inhibition, may play a
pivotal role in the polarization necessary for differentiation.
One critical role of RHAMM/xrhamm may be the accumu-
lation of TUBG1/tubg1 at the centrosome to influence microtu-
bule assembly [26,27] and interphase microtubule dynamics [28].
To further determine whether accumulation of microtubule-
associated factors was sufficient to disrupt polarization, RHAMM
and TUBG1, tagged with the green-fluorescent protein (GFP;
TUBG1-GFP), were constitutively over-expressed in MCF10A
cultures. Even in the presence of BRCA1, over-expression of
RHAMM produced significantly larger and less circular acini
(Figure 3C). Accordingly, over-expression of TUBG1-GFP (but
not GFP alone) impaired centrosome apical localization and
resulted in grape-like cell clusters with aberrant mitotic spindles
(Figure 3D). Therefore, increases in microtubule-associated
factors–through BRCA1 depletion, proteasome inhibition, or
over-expression of centrosome proteins targeted by BRCA1-
dependent ubiquitination–impair polarization. If decreased mi-
crotubule assembly at centrosomes is fundamental to BRCA1-
mediated polarization, concurrent depletion of BRCA1 and
associated factors may recover this process.
Interactions between AURKA, BRCA1, HMMR, and TPX2
Regulate Polarization
Active AURKA phosphorylates BRCA1 to influence interphase
microtubule assembly at the centrosome [52]; in turn, AURKA is
activated by a complex with targeting protein for Xenopus kinesin-
like protein 2 (TPX2) [53]. Therefore, to comprehensively
examine the molecular determinants of BRCA1-mediated polar-
ization, we evaluated the consequences of single and concurrent
depletions of AURKA, BRCA1, RHAMM, and TPX2 expression.
As with experiments targeting BRCA1 expression, depletion of
AURKA, RHAMM, and TPX2 was performed using individual
and pooled shRNAs, with transient or stable shRNA expression
assays, and over a time course of one or two weeks (Figures S4 and
S5). Note that depletions were not complete for any target, so
results should be interpreted in the context of partial loss-of-
function. Depletion of TPX2 did not impair growth, did not
disrupt polarization, and only slightly reduced the average acini
area (Figures 4A,B, S4, and S5). However, depletion of AURKA
significantly reduced two- and three-dimensional cellular growth
(Figures 4A,B, S4, and S5), which parallels the effect of a small
molecule inhibitor [54]. Finally, depletion of RHAMM induced
visible scattering in two-dimensional growth (Figure S4B) and
increased the area and altered the circularity of acini (Figures 4A,B,
S4, and S5). These results were further supported by observations
of VIM and CD49f immunostaining in acini (Figure S6). Thus,
alteration of RHAMM levels by over-expression or depletion
impairs polarization in a similar manner to BRCA1 depletion,
which suggests critical regulation of RHAMM in this process.
Having established the effects of single depletions, we
investigated the genetic interactions that regulate polarization.
Using concurrent, transient assays with pooled shRNAs, we
identified interactions between AURKA and HMMR (type double
nonmonotonic [55]), BRCA1 and TPX2 (type suppressive [55]),
and HMMR and TPX2 (type suppressive [55]) that regulate
polarization (Figure 4C). Notably, simultaneous depletion of
BRCA1 and RHAMM did not rescue the polarity defects of the
corresponding single depletion assays (Figure 4C, 4F, and 4G). In
fact, equivalent acini alterations were observed. As down-
regulation of a microtubule-associated factor (i.e., RHAMM) did
not recover BRCA1 depletion, a more complex regulation of
cytoskeletal reorganization during polarization may exist.
In contrast to single depletions, simultaneous reduction of
AURKA and RHAMM levels recovered normal acini formation
(Figure 4C–G), possibly implying a negative regulatory relation-
ship between RHAMM abundance and AURKA activity.
Although mechanistic insight into this relationship is lacking,
RHAMM depletion also protects against small-molecule inhibition
of AURKA in a different cell model [56]. Notably, depletion of
TPX2, the major activator of AURKA [53], recovered normal
acini formation with concurrent depletion of either BRCA1 or
RHAMM (Figure 4C, 4F, and 4G). Together, these genetic
interactions suggest that a balance between AURKA-TPX2 and
BRCA1-BARD1 activities, mediated by RHAMM, may deter-
mine proliferation and polarization.
Should AURKA antagonize BRCA1-BARD1 ubiquitination
activity to promote centrosome-dependent microtubule assembly
[52], AURKA depletion may amplify the degradation of BRCA1-
targeted molecules. As presented above, we confirmed this
relationship by examining RHAMM abundance, which was
augmented by BRCA1 depletion (Figure S7B and S7C).
Consistently, AURKA depletion reduced RHAMM levels (Figure
S7C), while simultaneous depletion of AURKA and BRCA1
recovered RHAMM to control levels (Figure S7C). Taken
together, these data indicate a critical relationship between
Figure 3. BRCA1 and RHAMM function in epithelial apicobasal polarization. (A) BRCA1 depletion (shRNA-mediated assay) impairs
polarization. Representative bright-field images are shown from control vector pLKO.1 and shRNA-BRCA1 (pLKO.1-based) transduced cultures. Scale
bars represent 20 mm. Confocal microscopy images of VIM immunostaining in control and BRCA1-depleted acini are shown. The graph shows results
for the area and shape factor measures from four independent experiments. Asterisks indicate significant differences (two-sided t test p,0.05) from
controls. (B) Proteasome inhibition (MG132 100 nM) significantly altered acini area and shape factor, and centrosome structure and polarity.
Representative bright-field images are shown from DMSO- or MG132-treated cultures. Confocal microscopy images for centrosome structure and
polarity (PCNT) in acini following proteasome inhibition, with nuclei counterstained with TOPRO (false color red), are shown. Arrows indicate altered
centrosome structures. The graph shows the results of at least three independent experiments. Average centrosome polarity was determined from
PCNT signal position within acini relative to nuclei. Across treatments, 33 acini were analyzed, averaging 24.7 centrosomes and nuclei/acini. Circles
indicate significant differences (two-sided t test p,0.005) to controls. (C) RHAMM over-expression (pLenti6.2-driven) impairs polarization.
Representative bright-field images are shown from control GFP vector or RHAMM (pLenti6.2-) transduced cultures. Middle panel, Western blot
analysis for RHAMM over-expression. The graph shows the results of four independent experiments. Values were normalized to untreated cultures
within experiments and differences evaluated from GFP controls. (D) TUBG1-GFP over-expression (pLenti6.2-driven) impairs polarization. MCF10A
were transduced with GFP or TUBG1-GFP expression constructs, selected with blasticidin and fluorescence-activated cell sorting. Sorted cells were
then analyzed for polarization in rBM and the resulting acini examined by bright-field and epifluorescence microscopy. GFP over-expression
permitted polarization (left panels). However, acini over-expressing TUBG1-GFP were unable to polarize (representative acini at bottom left in the
right panels). Blasticidin-resistant clones with low TUBG1-GFP expression formed normal acini with lumen, as indicated by DAPI (top right acini in the
bright-field image). Scale bars represent 20 mm.
doi:10.1371/journal.pbio.1001199.g003
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thus, polarization.
pT703-RHAMM Negatively Regulates AURKA Activity
through Nuclear Sequestration of TPX2
Complementary analyses suggest a BRCA1-HMMR interaction
linked to early-onset, ER-negative breast tumorigenesis, while
polarization studies suggest that RHAMM abundance is central to
BRCA1 and AURKA activities. As AURKA function relies upon
a physical association with TPX2 [53], we next investigated
protein complexes through the cell cycle to determine the
relationship between RHAMM abundance and AURKA activity.
Consistent with prior reports [26,27], co-immunoprecipitation
assays confirmed strong reciprocal interactions between RHAMM
and TPX2 during periods of microtubule re-organization (G2/M,
spindle assembly, and M/G1, spindle disassembly) (Figures 5A and
S8). Importantly, immunoprecipitation of BRCA1-associated or
TPX2-associated protein complexes revealed mobility-shifted
RHAMM species suggestive of phosphorylation (Figure S8).
Threonine 703 (T703) is an evolutionarily conserved phosphor-
ylated residue in RHAMM [57] similar to a consensus aurora
kinase Ipl1p site [58]. We carried out complementary analyses to
test this site as an AURKA substrate. Ectopic expression of GST-
AURKA increased levels of phosphoT703-RHAMM (pT703-
RHAMM) (Figure 5B), as detected by a novel polyclonal antibody
(Figure S9 and Materials and Methods). In MCF10A cells,
AURKA abundance and activity determined total RHAMM as
well as pT703-RHAMM levels (Figure S10A). An in vitro kinase
assay with recombinant AURKA confirmed T703-RHAMM site-
specific activity (Figure 5C). Finally, pT703-RHAMM was
reduced in a dose-dependent manner with AURKA inhibition
(Figures 5D and S10B) and with mitotic progression (Figure 5E),
which is consistent with AURKA degradation in anaphase [51].
Importantly, while total RHAMM was predominantly cytoplas-
mic with enrichment at microtubules and centrosomes, pT703-
RHAMM localized to interphase nuclei (Figure 5F). This
observation prompted the hypothesis that pT703-RHAMM
maintains homeostasis of AURKA activity by sequestering
TPX2 in the nucleus. Consistent with this hypothesis, pT703-
RHAMM immunoprecipitated with TPX2 during periods of high
AURKA activity (G2/M as previously described [52]) (Figures 5A
and S8), while RHAMM depletion not only redistributed TPX2 to
the cytoplasm and nuclear envelope (Figure 6A) but also increased
the level of TPX2 immunoprecipitated with AURKA (Figure 6B).
In addition, RHAMM depletion increased AURKA activity as
measured by an in vitro kinase assay with beads from AURKA
and TPX2 immunoprecipitations (Figure 6C). Collectively, these
data indicate that RHAMM maintains AURKA homeostasis as a
kinase substrate that, when phosphorylated, negatively regulates
AURKA-TPX2 complex formation. Moreover, these results
Figure 4. Genetic interactions influencing epithelial apicobasal polarization. (A) shRNA-mediated depletion of centrosome components
impairs polarization. Representative bright-field images are shown for results of untreated and control vector pLKO.1, shRNA-AURKA, shRNA-BRCA1,
shRNA-HMMR, or shRNA-TPX2 transduced cultures of MCF10A cells in rBM. Magnification is equivalent for all images and scale bars represent 20 mm.
(B) Acini architecture was quantified from bright-field images of cultures treated as described above. For comparison between experiments, all values
were normalized to untreated cultures within experiments and differences assessed statistically relative to pLKO.1. Shape factor values for single cells,
or small clusters, are not plotted. The graph shows the results of at least four independent experiments. For all graphs, asterisks and circles indicate
significant differences (two-sided t test p,0.05 and p,0.005, respectively) from controls (pLKO.1). (C) Representative bright-field images of acini from
concurrent depletions (shRNA-mediated) as indicated. (D) AURKA-HMMR interact in the regulation of polarization: HMMR depletion rescues the
abnormality seen in the shRNA-AURKA assay. Graph shows the results of three independent experiments. (E) Quantification of acini per well confirms
the genetic interaction between AURKA and HMMR. Graph shows the results of duplicate experiments. (F) TPX2 depletion is suppressive to
abnormalities caused by shRNA-BRCA1 and shRNA-HMMR. Graph shows the results of at least three independent experiments. (G) Prior to the shRNA
assays, published data proposed the hypothesis of a signaling pathway from TPX2 to RHAMM regulating polarization; degradation of the
microtubule-associated factor RHAMM, through BRCA1, was predicted as key to polarization. However, several observations from the single and
concurrent depletion assays (depleted proteins are indicated in grey font) diverged from the expected results (divergent observations are italicized).
RHAMM depletion impaired polarization in a manner that was rescued by concurrent depletion of AURKA or TPX2, but not BRCA1. On the other hand,
concurrent depletion of BRCA1 and TPX2 revealed normal acini.
doi:10.1371/journal.pbio.1001199.g004
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PLoS Biology | www.plosbiology.org 9 November 2011 | Volume 9 | Issue 11 | e1001199Figure 5. pT703-RHAMM functionally connects AURKA with BRCA1 and TPX2. (A) Molecular diagram of co-immunoprecipitation results
(Figure S8) between centrosome module components across the cell cycle, including complexes from pT703-RHAMM IPs (shown in red). (B) Over-
expression of GST-AURKA increases pT703-RHAMM. Lysates from HeLa cells, untreated or transfected with GST-AURKA, were immunoblotted for the
indicated proteins (GST-AURKA detected by anti-GST). (C) Position T703 of RHAMM is an AURKA substrate in vitro. When normalized to reactions
lacking substrate, the combination of recombinant AURKA, ATP, and a T703-containing peptide substrate (acetyl-CKENFALK(T)PLKEGNT-amide)
resulted in time-dependent consumption of ATP as measured by luminescence. In contrast, a pre-phosphorylated (PO4) T703-containing peptide
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with BRCA1, impairs polarization through augmentation of
AURKA activity.
pT703-RHAMM Expression in BRCA1 Mutant Breast
Cancer Cells and Tumors; A Mechanistic Model for
Polarization and Increased Risk of Breast Cancer
The data above indicate that a balance between BRCA1-
mediated turnover and AURKA-mediated phosphorylation of
RHAMM regulates polarization versus proliferation. To evaluate
the link with carcinogenesis, pT703-RHAMM immunochemistry
was performed in BRCA1 mutant breast cancer cells, HCC1937
line, their wild-type reconstituted counterparts, and in primary
breast tumors. As a result, pT703-RHAMM staining was revealed
to be strong at the nuclear envelope of HCC1937 cells but
homogenous and less intense in the nucleus of the reconstituted cells
(Figure 7A). Subsequently, high expression of pT703-RHAMM was
scored in 58% (n=11) and 50% (n=4)ofBRCA1 mutation carriers
and sporadic ER-negative tumors, respectively, but in 36% (n=5)
and 30% (n=10) of BRCA2 mutation carriers and sporadic ER-
positive tumors, respectively (Figure 7B). Although this dataset is
limited, the results support the indication of an interplay between
BRCA1 and RHAMM, which is altered in breast carcinogenesis.
Our data delineate a model in which different types of
relationships between high- and low-penetrance breast cancer
susceptibility genes and their products regulate the polarization
necessary for terminal differentiation of luminal epithelia. That is,
BRCA1 and AURKA activities, as regulated by RHAMM and
TPX2, control this transition and regulate cellular proliferation
and differentiation (Figure 8). In this model, concurrent depletion
of BRCA1 and RHAMM does not recover normal acinar
morphogenesis because target degradation of RHAMM may be
restricted to late phases of polarization. This model is consistent
with reduced expression of AURKA, TPX2, and HMMR, but to a
Figure 6. RHAMM depletion alters TPX2 localization and AURKA activity. (A) Depletion of RHAMM, but not BRCA1, results in re-localization
of TPX2 from the nucleus to the nuclear envelope and cytoplasm (arrows). With RHAMM depletion, microtubule organization is less focused and
radial. Scale bar represents 20 mm. (B) RHAMM depletion alters AURKA-TPX2 association. In triplicate experiments, MCF10A were untreated or
depleted of BRCA1 or RHAMM, and lysates were immunoprecipitated with AURKA, TPX2, or control IgG antibodies. Compared to untreated or BRCA1-
depleted samples, RHAMM depletion resulted in an increase of TPX2 co-precipitated with AURKA. Short and long Western blot exposures are shown.
(C) RHAMM depletion alters AURKA activity. Immunoprecipitation beads from triplicate experiments were analyzed for kinase activity using
luminescent detection of ATP. Luminescence values were normalized to those obtained for beads precipitated with control IgG. Beads from
untreated lysates precipitated with AURKA but not TPX2 antibodies demonstrated modest kinase activity. Depletion of RHAMM led to a significant
increase in kinase activity with both AURKA and TPX2 precipitation (asterisks indicate one-sided t test p,0.05). Graph shows means and standard
errors from triplicate experiments.
doi:10.1371/journal.pbio.1001199.g006
(acetyl-CKENFALK(PO4-T)PLKEGNT-amide) showed muted AURKA activity. Asterisk and circles indicate significant differences (two-sided t test p#0.05
and p,0.005, respectively) relative to control condition (no peptide). (D) AURKA inhibition results in specific loss of pT703-RHAMM. Lysates of HeLa
treated with graded concentrations of an AURKA inhibitor (see Materials and Methods) were immunoblotted for the indicated endogenous proteins.
(E) pT703-RHAMM cellular immunoreactivity is lost post-metaphase. Consistent with previous reports [23,63,76], total RHAMM decorates all
microtubule structures throughout mitosis. In contrast, pT703-RHAMM is lost, or reduced, on microtubule structures after metaphase (arrows).
Interphase cells within the field of view indicate specific loss of pT703-RHAMM post-metaphase. The indicated mitotic stage was determined by
microtubule organization and DNA condensation (unpublished data). (F) pT703-RHAMM localizes to nuclear compartments. pT703-RHAMM localizes
to the nucleus and nuclear envelope. An in-frame post-metaphase cell indicates that nuclear labeling is specific to interphase. Magnification is
equivalent for all images and scale bar represents 10 mm.
doi:10.1371/journal.pbio.1001199.g005
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nonmalignant mammary epithelial cells, as measured by gene
expression profiling (Figure S11A) [59]. Deviation from this
pathway, through loss of BRCA1 function or augmentation of
microtubule-associated factors, may impair terminal differentia-
tion of luminal epithelia and promote tumorigenesis. Consistently,
HMMR over-expression might be detectable as early as the
transition from normal breast tissue to hyperplasia (Figure S11B)
[60]. In our cellular assays for polarization, however, concurrent
BRCA1 depletion and RHAMM over-expression did not result in
an additive disruption of polarity, perhaps due to the non-additive
alteration of RHAMM abundance and variable BRCA1 depletion
(Figure S12). According to the model and as stated above, analysis
of public gene expression datasets suggests that the rs299290 risk
allele is associated with HMMR germline over-expression (Table
S3) [23]. As the potential splicing alteration by rs299284 might be
tissue specific and RHAMM-R92 was used in the over-expression
assays, further work may be warranted to define the causal
mutation(s) and the alteration of RHAMM function and/or
expression level according to the depicted model.
Discussion
We have investigated gene and protein interactions in a
centrosome-cantered module, including BRCA1/BRCA1 and
HMMR/RHAMM, across biological systems ranging from breast
cancer risk estimates to cellular phenotypes and cytoskeletal
structures. Consistent findings between these systems provide
insights into diverse processes and conditions. First, the key role of
this module in epithelial apicobasal polarization suggests that
genetic variation in its components might influence risk of breast
cancer. Accordingly, a common candidate breast cancer-predis-
position allele in HMMR, originally identified in an Ashkenazi
Jewish study [23], may specifically modify breast cancer risk
among BRCA1 mutation carriers. Population-discordant results for
HMMR [61], and possibly for other components of this module
(i.e., AURKA [62]), might be due to genetic differences between
populations. A recent report has suggested that common genetic
variation in genes encoding for centrosome pathway components
(excluding AURKA and HMMR) may frequently influence risk of
breast cancer and, notably, includes variants in TACC3–a
proposed HMMR homolog [63]–TUBG1, and TPX2 loci [64].
Figure 7. pT703-RHAMM expression in BRCA1 mutant breast cancer cells and tumors. (A) pT703-RHAMM staining is strong at the nuclear
envelope of HCC1937 cells (BRCA1 mutated or transduced with an empty vector; left and middle panels, respectively) but homogeneous nuclear in
BRCA1 wild-type reconstituted cells (right panel). (B) Results of pT703-RHAMM staining scores in primary breast tumors with different BRCA1/2
mutation and ER status. Results correspond to scores from two pathologists (see Materials and Methods).
doi:10.1371/journal.pbio.1001199.g007
Figure 8. Mechanistic model of interplay between AURKA,
BRCA1, RHAMM, and TPX2 that regulates proliferation versus
polarization. Proliferation is proposed to be linked to an active (‘‘on’’)
status of AURKA while differentiation would be linked to an active
BRCA1 status, both centered on tight regulation of RHAMM level and
localization.
doi:10.1371/journal.pbio.1001199.g008
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evaluations of the interactions between cancer susceptibility genes
and their products across systems to delineate the potential
relationship with carcinogenesis [65].
A unifying mechanism of breast carcinogenesis linked to
BRCA1 loss-of-function should provide a comprehensive expla-
nation for the observed accumulation of stem and luminal
progenitor cells [17–19], and for the characteristic pathological
features of the corresponding tumors [11,12]. The results of our
study suggest that BRCA1 promotes the polarization necessary for
luminal differentiation, in part, by orchestrating the dynamic
transition to microtubule assembly at non-centrosome sites (i.e.,
cell-to-cell contacts). Transition to microtubule anchorage at
adherens junctions regulates epithelial cell-to-cell contacts [9] that,
in turn, instruct mammary stem cell fate and differentiation [66].
Thus, the switch to non-centrosome-dependent assembly of
microtubules may be essential in discriminating between prolifer-
ating and differentiated cells, as also observed recently in
myoblasts [67] and neurons [68]. Should BRCA1 function(s)
promote this transition in mammary stem/progenitor cells,
impaired luminal differentiation in BRCA1 mutation carriers and
a propensity to develop basal-like tumors with elevated prolifer-
ative capacity would be expected. Further studies using different
polarization and/or differentiation cellular models may be
warranted to corroborate the depicted mechanism.
Proliferation is promoted by activated AURKA but, as occurs in
tightly synchronized cell cycle events [69], possibly regulated
through a negative feedback loop as identified in this study. In
preparation for mitotic spindle assembly, AURKA promotes
centrosome-dependent microtubule assembly by suppressing
BRCA1-dependent ubiquitination [52], which involves BRCA1
phosphorylation at S308 [70]. Subsequently, terminal differenti-
ation is proposed to be mediated by BRCA1 activation and
RHAMM degradation. Accordingly, BRCA1 depletion increases
the clonogenic potential of mammary epithelia [14–16], while a
BRCA1 S308A mutant alters embryonic stem cell differentiation
[71]. Moreover, RHAMM abundance may be central to the
balance between AURKA-TPX2 and BRCA1-BARD1 activities
during polarization; consistently, depletion of RHAMM also
impairs ciliary differentiation of human respiratory epithelial cells
[72]. However, key components of the depicted molecular wiring
diagram are probably missing, such as a phosphatase that
regulates AURKA-mediated modification of BRCA1 and
RHAMM. Additionally, loss of BRCA1 function is likely to alter
complementary pathways such as the regulation of epithelial-
mesenchymal transition [19] and androgen receptor signaling
[73].
A key question remains regarding the significance of BRCA1
function to stem/progenitor differentiation and BRCA1 haploin-
sufficiency. Examination of histologically normal breast tissue in
BRCA1 mutation carriers revealed cellular foci expressing stem cell
markers and lacking cytoskeletal structures characteristic of
luminal epithelia [16]. Here, we suggest an alteration of
polarization in preneoplastic lesions. Neither of these presentations
is as severe as those observed in murine mammary epithelial
tissues reconstituted from human cells depleted of BRCA1 [19].
Thus, BRCA1 dose or mutation type may distinctly affect the tissue
architecture and function, leading to differences in the accumu-
lation of stem or progenitor cells, and the resulting tumor type
[74]. More detailed examination of mammary gland histology and
function may reveal specificities in BRCA1 mutation carriers
reflective of a gradient in the disruption of luminal differentiation.
To summarize, this study describes a mechanistic model in which
high- and low-penetrance breast cancer susceptibility genes and
their products are connected through a series of genetic,
molecular, and functional interactions that, when perturbed, alter
proper epithelial apicobasal polarization and may lead to an
increased risk of breast cancer.
Materials and Methods
Ethics Statement
BRCA1 and BRCA2 mutation carriers were recruited under the
CIMBA initiative following approval of the corresponding
protocols by institutional review boards or ethics committees at
each participating centre, as described [32,33].
Study Samples, Genotyping, and Statistical Analyses
Study acronyms are detailed in Table S2. The NICCC centre in
Israel followed similar protocols and similar approval processes.
Deviation from Hardy-Weinberg equilibrium was evaluated
among unrelated participants separately for each study. Risk
estimates and significance testing were computed using standard
and weighted Cox regression models [35] that included centre,
country, and birth cohort (,1940, 1940–1949, 1950–1959, and
$1960) as stratification factors and ethnicity as the covariate for
adjustment. A robust variance estimate was used to account for
familial correlation. Time to diagnosis of breast cancer from birth
was modeled by censoring at the first of the following events:
bilateral prophylactic mastectomy, breast cancer diagnosis,
ovarian cancer diagnosis, death, and last date known to be alive.
Participants were considered affected if they were censored at
breast cancer diagnosis and unaffected otherwise. The weighted
cohort approach involves assigning weights separately to affected
and unaffected individuals such that the weighted observed
incidences in the sample agree with established estimates for
mutation carriers [35]. This approach has been shown to adjust
for the bias in the HR estimates resulting from the ascertainment
criteria used, which leads to an over-sampling of affected women.
Weights were assigned separately for carriers of mutations in
BRCA1 and BRCA2 and by age interval (,25, 25–29, 30–34, 35–
39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, $70). Polymor-
phism data were analyzed as a three-group categorical variable
(codominant model) and using restricted inheritance models (log-
additive, dominant and recessive). The p values were derived from
the robust score test. All statistical analyses were carried out using
R software. Linkage analysis was performed with GENEHUN-
TER version 2.1 [75].
Cell Culture
HeLa (American type culture collection, ATCC), 293FT
(Invitrogen), and MCF10A (ATCC) were cultured in media as
recommended. For growth factor-reduced experiments, media
(HuMEC from Invitrogen or HMEC from Lonza) contained 1/3
recommended hEGF. Growth in rBM (Cultrex from Trevigen or
Geltrex from Invitrogen) followed embedded or on-top techniques
as described [45]. MCF10A were embedded in rBM for
proteasome inhibition (MG132; Sigma-Aldrich) experiments; for
other endpoints, embedded and on-top conditions were equiva-
lent. For rBM growth, MG132 or equivalent DMSO volumes
were added to media at seeding, or as indicated, for two days. For
proteolysis protection, MG132 (1.5 mM) was added for 3 h prior to
lysis. For AURKA inhibition, a commercially available AURKA
inhibitor (C1368; Sigma-Aldrich) was titrated and used at
100 nM. For TUBG1-GFP expression, MCF10A were transduced
with a lentiviral-based vector, sorted, and selected for blasticidin
resistance (pLenti6.2/EmGFP-DEST, Invitrogen).
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For expression in MCF10A, RHAMM and TUBG1-GFP were
subcloned into pDONR223 (Invitrogen), sequenced, and trans-
ferred to pLenti6.2/V5-DEST following the manufacturer’s
instructions (Invitrogen). All constructs maintained native stop
codons. Depletion assays used MISSION shRNA sequences
(Sigma-Aldrich), shown in Table S5. The lentiviral packaging,
envelope, control, and GFP expression plasmids (psPAX2,
pMD2.G, non-hairpin-pLKO.1, scrambled-pLKO.1, and
pWPT-GFP) were purchased from Addgene. Production and
collection of lentiviral particles followed a modified Addgene
protocol. Initial viral titres .5610
5/ml were confirmed by Lenti-
X GoStix (Clontech) and supernatants were then concentrated by
ultracentrifugation or Lenti-X Concentrator (Clontech) and stored
at 280uC. Concentrated viral supernatants were titrated for
optimal inhibition of target gene products, by immunoblot at 5 d,
and MCF10A survival. For shRNA-mediated depletion of
BRCA1, four shRNA species were purchased and tested; these
sequences were distinct from that previously described [14]. For
depletion of AURKA, RHAMM, and TPX2, five shRNA
constructs were purchased for each gene (Sigma-Aldrich). Initial
experiments used combinations of shRNAs targeting individual
genes (up to five sequences per gene) at a multiplicity of infection
of five. For confirmation experiments, individual and redundant
constructs were identified with high knockdown efficacy. Two
shRNA sequences effectively reduced the expression of AURKA
(59-ACGAGAATTGTGCTACTTATA-39 and 59-CCTGTC-
TTACTGTCATTCGAA-39), BRCA1 (59-CACCTAATTG-
TACTGAAT-39 and 59-TACAAGAAAGTACGAGAT-39), and
RHAMM (59-CGTCTCCTCTATGAAGAACTA-39 and 59-
GCCAACTCAAATCGGAAGTAT-39), respectively. These
shRNAs have also been independently validated for reduction in
mRNA levels by the manufacturer (67%–87% reduction, Sigma-
Aldrich). Only one sequence efficiently reduced expression of
TPX2 (59-CCGAGCCTATTGGCTTTGATT-39). Transient
transfection of GST-AURKA in HeLa and MCF10A followed
the manufacturers’ suggested protocols for Lipofectamine 2000
(Invitrogen) or FuGENE (Roche).
Biochemical Assays
Synchronization and immunoprecipitation, and immunofluo-
rescence of cells and acini, were performed as described
previously [27,45]. For immunofluorescence analysis, cells were
mounted in 90% glycerol/PBS and counterstained with DAPI or
TOPRO. The in vitro kinase assay with recombinant HIS-
AURKA (PTP055, Cell Science) followed the protocol for the
PKLight HTS Protein Kinase Assay Kit (Lonza), as suggested by
the manufacturer. Reactions were performed in triplicate.
Luminescence values were normalized to the mean value for
no-substrate (HIS-AURKA alone) reactions. The activity of
endogenous AURKA was determined by performing the kinase
assay with ATP, substrate, and immunoprecipitation beads_IgG
(negative control), anti-AURKA (positive control), or anti-TPX2
from MCF10A lysates but without recombinant AURKA.
Consumption of ATP was determined after incubation for
30 min.
Antibodies
For total RHAMM, a previously developed and characterized
polyclonal antibody (originally named anti-IHABP) was used
[24,76]. The specificity of this antibody has been further evaluated
elsewhere (see also Figure S9) [23,27]. The phosphorylation-
specific polyclonal antibody against pT703-RHAMM is a custom
reagent generated by New England Peptide. For this antibody,
unpurified and purified sera were tested for specificity relative to
the RHAMM-total antibody defined above. These assays included
immunoblots with shRNA-mediated depletion of RHAMM
(Figure S9). Other antibodies included anti-ACTB (A5060,
Sigma-Aldrich), anti-AURKA (1G4, Cell Signaling Technology),
anti-BRCA1 (SD118, Calbiochem), anti-CD49f (4F10, Millipore),
anti-CDH1-Alexa 488 (24E10, Cell Signaling Technology), anti-
GST (GE healthcare), anti-MYC (9E10, Sigma-Aldrich), anti-
PCNT (Covance), anti-TUBA (B512, Sigma-Aldrich), anti-TUBB-
Alexa 647 (9F3, Cell Signaling Technology), anti-TUBG1
(GTU88, Sigma-Aldrich), and anti-VIM (V9, Sigma-Aldrich; or
R28, Cell Signaling Technology). Secondary antibodies for
immunofluorescence (Alexa) were obtained from Molecular
Probes (Invitrogen) and GE Healthcare for immunoblot analysis
(HRP-conjugated).
Image Acquisition and Quantitation
Blind deconvolution with AutoQuant (AutoQuant Imaging Inc.)
was performed on images from an Axiovert microscope with Plan-
Apochromat 636objective (Zeiss) (numerical aperture (NA) 1.25)
with Z-steps from 0.5–1.0 mm. Alternatively, a Leica DMI 6000
laser scanning confocal microscope equipped with a Leitz HCX
Pl-Apo CS 406 oil objective (1.25 NA) captured images as
indicated. Epifluorescence images were acquired with an Olympus
BX-60 using a Spot camera and Spot3.2.4 software (Diagnostic
Instruments). For quantitation of growth in rBM, bright-field
images of acini were analyzed for size and shape with ImageJ
software (National Institutes of Health). For shape analysis, the
square of the inverse of circularity was plotted. The position of the
centrosome relative to the lumen, or centre of the cellular cluster,
was measured using pericentrin immunofluorescence or TUBG1-
GFP in image stacks.
Breast Cancer Cell Line, Tumors, and Immunochemistry
In order to reconstitute HCC1937 cells with wild-type BRCA1,
the corresponding full-length open-reading frame was cloned into
a retroviral vector S11N and transduced. Assays with the empty
vector were used as controls. Cells were fixed in 2% paraformal-
dehyde and immunochemistry carried out following a standard
labelled streptavidin biotin (LSAB) method. For tumors, immu-
nohistochemical staining was performed by the Envision method
(Dako, Glostrup, Denmark), with a heat-induced antigen retrieval
step. Sections from the tissue array were immersed in 10 mM
boiling sodium citrate at pH 6.5 for 2 min in a pressure cooker,
and antibodies were used at dilution of 1:1,500 and 1:1,000 for
pT703-RHAMM and TUBG1, respectively. Scoring for pT703-
RHAMM was performed in a blind and independent manner by
two pathologists with an initial correlation value of 0.75.
Discordant results were then assessed jointly but blind from the
genetic status of the samples. Hyperplastic lesions in BRCA1
mutation carriers were also assessed by both pathologists.
Supporting Information
Figure S1 Evaluation of potential alteration of the HMMR
splicing pattern by rs299284 variation. Lymphocytes from 10
BRCA1 mutation carriers were isolated and DNA and RNA
samples purified for genotyping and expression analyses, respec-
tively. Five major homozygotes and five heterozygotes for
rs299284 were identified, which revealed complete linkage
disequilibrium with rs299290 (unpublished data). Next, reverse
transcriptase polymerase chain reactions (30 cycles) were carried
out with forward (59-GACAAAGATACTACCTTGCCTGCT-
39) and reverse (59-CAGCATTTAGCCTTGCTTCCATC-39)
BRCA1-RHAMM and Breast Carcinogenesis
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Variation at rs29984 (marked by an arrow) does not alter the exon
5 acceptor donor site or the exon 4 inclusion/exclusion ratio.
Sample identifiers are shown.
(TIF)
Figure S2 MCF10A cells grown in rBM establish apicobasal
polarity and attenuate expression of VIM. (A) Apicobasal polarity
and luminal characteristics were confirmed with immunofluores-
cence. The a6-integrin (CD49f) is deposited at the basal surface
upon polarization and the expression of VIM is lost with this
transition (acini #1–4). Some acini (#5) fail to polarize and do not
deposit CD49f. These acini express VIM and grow larger with
diminished circularity. Scale bars represent 20 mm. (B) Acini
imaged with bright-field microscopy at low magnification (106).
Scale bar represents 100 mm. Quantitation of acini size and shape
with ImageJ software distinguishes polarized from non-polarized
acini (quantitation performed on images from 206magnification
are not shown). Normalization to controls allows comparison
across replicate experiments. For display purposes, the shape
factor was plotted such that values .1 indicate abnormal
polarization.
(TIF)
Figure S3 Loss of centrosome polarity in breast hyperplastic
lesions of BRCA1 mutation carriers. (A) Normal luminal structure
showing apical localization of the centrosomes (TUBG1) in a tissue
donor (unaffected, left panel) and in a BRCA1 mutation carrier
(right panel). Arrows mark properly, lumen-oriented centrosomes
in many cells. (B) Three hyperplastic lesions showing loss of
polarity in BRCA1 mutation carriers. Left panels show hematox-
ylin-eosin staining and the insets correspond to the middle and
right panels with results for TUBG1 staining. Loss of polarity is
evidenced by the identification of centrosome signals that are not
oriented towards the lumen and/or that are located on top of the
nuclei (arrows).
(TIF)
Figure S4 Stable depletion of centrosome components deter-
mines epithelial apicobasal polarization at an early time-point. (A)
Transduction of single or pooled shRNAs targeting the expression
of indicated proteins was identified resulting in detectable
depletions. Sequences for the indicated shRNA are given in Table
S5. (B) Representative bright-field images (low magnification, 206)
for adherent (day 6, plastic) and rBM (day 7, on-top) growth of
untreated and puromycin-resistant MCF10A cells transduced with
pLKO.1-nonhairpin, shRNA-AURKA, shRNA-BRCA1, shRNA-
HMMR, or shRNA-TPX2. Scale bars represent 100 mm. (C) Acini
architecture was quantified from bright-field images of cultures
treated as indicated at 1 week post-plating. For comparison
between experiments, all values were normalized to pLKO.1-
transduced cultures within experiments. Shape factor ((1/circu-
larity)
2) values for single cells or small clusters are not plotted
(shRNA-AURKA). Asterisks and circles indicate significant differ-
ences (two-sided t test p,0.05 and p,0.005, respectively) from
controls (pLKO.1).
(TIF)
Figure S5 Transient depletion of centrosome components
determines epithelial apicobasal polarization at early and late
time-points. (A) Representative bright-field images (low magnifi-
cation, 56) for rBM (second week, embedded) growth of MCF10A
transduced with virus encoding pLKO.1-nonhairpin, or individual
(as indicated) or pooled shRNAs targeting the expression of
AURKA, BRCA1, RHAMM, or TPX2. Images are scaled
equivalently, with the scale bar representing 200 mm. (B) Acini
architecture was quantified from bright-field images (106
magnification) of cultures treated as indicated at 1 week post-
plating. For comparison between experiments, all values were
normalized to pLKO.1-transduced cultures within experiments.
Shape factor values for single cells or small clusters are not plotted
(shRNA-AURKA). Asterisks and circles indicate significant differ-
ences (two-sided t test p,0.05 and p,0.005, respectively) from
controls (pLKO.1). (C) Acini architecture was quantified from
bright-field images (106 magnification) of cultures treated as
indicated at 2 weeks post-plating.
(TIF)
Figure S6 Depletion of centrosome components alters the
expression profile of VIM and CD49f. In normal acini (control
and shRNA-TPX2), centrosomes are apically positioned (TUBG1),
CD49f is deposited at the basal surface, and VIM is lost. This
pattern is altered with depletion of BRCA1 or RHAMM. Acini
size and shape are reflective of polarization. Results are shown for
the nonhairpin pLKO.1 control, shRNA-AURKA (#3), shRNA-
BRCA1 (#34), shRNA-HMMR (#4), and shRNA-TPX2 (pooled)
assays.
(TIF)
Figure S7 AURKA and BRCA1 activity determine RHAMM
abundance. (A) AURKA and RHAMM are protected by
proteasome inhibition. Lysates of MCF10A cells exposed for 3 h
to DMSO or MG132 were immunoblotted for the indicated
proteins. (B) BRCA1 depletion protects RHAMM, but not
AURKA, from degradation. Lysates of MCF10A cells growing
in growth factor (GF)-reduced media exposed to MG132 or
depleted of BRCA1 were immunoblotted for the indicated
proteins. (C) Interplay between AURKA and BRCA1 activity
regulates RHAMM abundance. Lysates from MCF10A cultures
transduced with control vector pLKO.1, shRNA-AURKA, shRNA-
BRCA1, shRNA-HMMR, or shRNA-TPX2, or simultaneously with
shRNAs-AURKA/BRCA1, were immunoblotted for the indicated
proteins. shRNA-AURKA depletion reduces AURKA as well as
RHAMM and TPX2, both cell-cycle-regulated proteins (Figure
S8). shRNA-BRCA1 reduces BRCA1 and specifically increases
RHAMM, which is consistent with previous data [23] and a
putative role of BRCA1 in proteasome-mediated degradation of
RHAMM. shRNA-HMMR and -TPX2 reduce RHAMM and
TPX2 levels, respectively. Compared to single depletions,
simultaneous depletion of AURKA and BRCA1 normalizes
RHAMM levels but not those of TPX2.
(TIF)
Figure S8 Protein complexes during the cell cycle. (A) HeLa
cells were harvested at confluence (unsynchronized, Us) or
following synchronization with double thymidine (S), double
thymidine/nocodazole (G2/M), or release from these blocks for
3 and 5 h (S/G2 and M/G1, respectively). Synchronization was
confirmed by bright-field microscopy and FACS analysis. (B)
AURKA, RHAMM, and TPX2 show cell-cycle-regulated expres-
sion in whole-cell extracts (WCEs; antibodies are those used in the
rest of the study). (C) Examination of post-immunoprecipitation
fractions confirmed the efficiency of the assays. Lysates following
immunoprecipitation were loaded equivalently and analyzed by
immunoblot to determine efficacy. (D) Protein complexes are
dynamic during the cell cycle. Lysates following immunoprecip-
itation were loaded and analyzed by immunoblot. Arrows indicate
RHAMM species with retarded mobility potentially indicative of
phosphorylation. (E) As described above for AURKA, RHAMM,
and TPX2, pT703-RHAMM shows cell-cycle-regulated expres-
sion in WCEs. Lysates following immunoprecipitation were loaded
and analyzed by immunoblot with anti-pT703-RHAMM. Arrows
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lower bands in AURKA, BRCA1, and TPX2 immunoprecipita-
tions is consistent with total RHAMM.
(TIF)
Figure S9 Evaluation of pT703-RHAMM polyclonal antibody.
(A) Specificity of pT703-RHAMM antibody was confirmed by
immunoblot analysis. Inoculating peptide is shown. Lysates from
HeLa were loaded equivalently and probed with a positive control
anti-RHAMM antibody (originally named anti-IHABP). Prebleeds
and bleeds from two rabbits and affinity purified antibodies against
pT703 were tested by immunoblot. (B) Specificity of pT703-
RHAMM antibody was confirmed by immunoblot analysis
following shRNA-HMMR. Lysates from HeLa were loaded
equivalently. Reduction in pT703-RHAMM signal was revealed
following shRNA-mediated depletion of HMMR expression.
(TIF)
Figure S10 AURKA phosphorylates and regulates RHAMM
levels. (A) AURKA abundance determines RHAMM and pT703-
RHAMM levels. MCF10A cells were grown in GF-reduced media
to decrease endogenous levels of RHAMM. Lysates of MCF10A
cells transfected with GST-AURKA or transduced with shRNA-
AURKA were analyzed by immunoblot analysis and compared to
untreated (non-transfected and non-transduced, respectively).
Abundance of both total RHAMM and pT703-RHAMM was
altered by AURKA abundance. shRNA-AURKA reduces
RHAMM levels while GST-AURKA augments RHAMM levels,
consistent with the described reduction of BRCA1-mediated
ubiquitination by AURKA [52] and interplay between AURKA
and BRCA1 in regulating RHAMM abundance (Figure S7). (B)
AURKA inhibition decreases pT703-RHAMM and, to a lesser
extent, total RHAMM. Lysates of MCF10A treated with graded
concentrations of an AURKA inhibitor (see Materials and
Methods) were immunoblotted for the indicated proteins.
(TIF)
Figure S11 Expressionprofilesinmammaryepithelialcellsandin
early stages of breast carcinogenesis. (A) Profiles of AURKA, BRCA1,
HMMR, and TPX2 in nonmalignant human mammary epithelial
cells (immortalized clone HMT3522 S1, left panel; nonimmorta-
lized clone HMEC 184, right panel) across days 3, 5, and 7 (two
replicates for each time point are shown) in three-dimensional
cultures [59]. The graphs show results for all microarray probes of
the corresponding genes and p values of the lineal regression
analyses. (B) HMMR expression differences between histologically
normal (HN) tissues versus patient-matched atypical ductal
hyperplasia (ADH) and ductal carcinoma in situ (DCIS). The
graphs show results of two microarray probes (names shown at the
top) and the corresponding significance p values (two-sided t test).
(TIF)
Figure S12 Effect of concurrent BRCA1 depletion and
RHAMM over-expression in polarization. (A) MCF10A cells were
transduced with a shRNA targeting BRCA1 (#34) or control
(pLKO.1). Additionally, cells were transduced with, or without, a
vector (pLenti6.2) driving RHAMM expression. Multiplicity of
infection was kept at five for single and dual transductions. Lysates
were prepared 5 d post-transduction. (B) MCF10A cells, treated as
indicated, were seeded in rBM to undergo polarization. After 2
weeks culture, acini were imaged and area and shape values were
scored. Values were normalized to untreated controls.
(TIF)
Table S1 Variants typed in 5q34 to produce a NPL score
(affected only analysis) of 4.24 among BRCA1 mutation carrier
families.
(XLS)
Table S2 Estimates (per allele wHR) of modification of breast
cancer risk by HMMR rs299290 among BRCA1 mutation carriers.
(XLS)
Table S3 Association of rs299290-C with germline HMMR
over-expression.
(XLS)
Table S4 Genotypes of rs299290 and ER-tumor status in
BRCA1/2 mutation carriers.
(XLS)
Table S5 shRNA sequences used in this study.
(XLS)
Text S1 Supplementary Materials and Methods.
(DOC)
Text S2 Additional acknowledgments.
(DOC)
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